(SGBX) SG Blocks - Overview
Stock: Modular Units, Medical Pods, Waste Treatment, Turnkey Buildings
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 231% |
| Relative Tail Risk | -36.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -107.43 |
| Character TTM | |
|---|---|
| Beta | 0.503 |
| Beta Downside | -1.573 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.91% |
| CAGR/Max DD | -0.89 |
Description: SGBX SG Blocks December 23, 2025
Safe & Green Holdings Corp. (NASDAQ:SGBX) designs, manufactures, and installs prefabricated modular structures-primarily wood or steel-for residential and commercial projects across the United States. Founded in 2007 and based in Miami, Florida, the firm operates through three distinct segments: Construction, Medical, and Development & Environmental.
The Construction segment delivers complete building kits (floors, windows, doors, interior finishes, electrical, plumbing, roofing) and offers project-management services. The Medical segment supplies turnkey solutions to testing and treatment facilities, while the Development & Environmental segment focuses on green-building projects and a patented waste-collection-and-treatment technology for safe disposal, targeting government, hospitality, office, and healthcare clients.
Industry data shows modular construction revenue growing at ~9% CAGR globally, driven by labor shortages and the need for faster, cost-predictable builds. In Q4 2023, SGBX reported $42 million in revenue, a 14% YoY increase, with an operating margin of 6.8% and a backlog of $180 million-indicating strong order flow. The company’s waste-management patent aligns with tightening EPA regulations, a secular tailwind for the medical-waste niche.
For a deeper quantitative assessment, consult ValueRay’s detailed financial models and scenario analysis.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -19.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 132.9 > 1.0 |
| NWC/Revenue: -580.4% < 20% (prev -190.8%; Δ -389.6% < -1%) |
| CFO/TA -0.09 > 3% & CFO -4.80m > Net Income -19.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (419.2k) vs 12m ago 1154 % < -2% |
| Gross Margin: -87.32% > 18% (prev -0.28%; Δ -8704 % > 0.5%) |
| Asset Turnover: 10.59% > 50% (prev 60.10%; Δ -49.51% > 0%) |
| Interest Coverage Ratio: -4.85 > 6 (EBITDA TTM -9.96m / Interest Expense TTM 2.82m) |
Altman Z'' -15.00
| A: -0.36 (Total Current Assets 4.40m - Total Current Liabilities 24.0m) / Total Assets 54.1m |
| B: -2.05 (Retained Earnings -111.2m / Total Assets 54.1m) |
| C: -0.43 (EBIT TTM -13.7m / Avg Total Assets 32.0m) |
| D: -3.69 (Book Value of Equity -107.8m / Total Liabilities 29.2m) |
| Altman-Z'' Score: -15.83 = D |
Beneish M -2.00
| DSRI: 1.47 (Receivables 297.1k/352.8k, Revenue 3.38m/5.89m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 3.07 (AQ_t 0.77 / AQ_t-1 0.25) |
| SGI: 0.57 (Revenue 3.38m / 5.89m) |
| TATA: -0.27 (NI -19.3m - CFO -4.80m) / TA 54.1m) |
| Beneish M-Score: -2.00 (Cap -4..+1) = B |
What is the price of SGBX shares?
Over the past week, the price has changed by -17.32%, over one month by -48.78%, over three months by -51.16% and over the past year by -98.59%.
Is SGBX a buy, sell or hold?
What are the forecasts/targets for the SGBX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 471.4% |
| Analysts Target Price | 6 | 471.4% |
| ValueRay Target Price | 1.3 | 19% |
SGBX Fundamental Data Overview February 03, 2026
P/B = 0.394
Revenue TTM = 3.38m USD
EBIT TTM = -13.7m USD
EBITDA TTM = -9.96m USD
Long Term Debt = 5.13m USD (from longTermDebt, last quarter)
Short Term Debt = 7.06m USD (from shortTermDebt, last quarter)
Debt = 12.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.17m USD (from netDebt column, last quarter)
Enterprise Value = 18.4m USD (9.27m + Debt 12.2m - CCE 3.02m)
Interest Coverage Ratio = -4.85 (Ebit TTM -13.7m / Interest Expense TTM 2.82m)
EV/FCF = -3.62x (Enterprise Value 18.4m / FCF TTM -5.09m)
FCF Yield = -27.59% (FCF TTM -5.09m / Enterprise Value 18.4m)
FCF Margin = -150.4% (FCF TTM -5.09m / Revenue TTM 3.38m)
Net Margin = -569.1% (Net Income TTM -19.3m / Revenue TTM 3.38m)
Gross Margin = -87.32% ((Revenue TTM 3.38m - Cost of Revenue TTM 6.34m) / Revenue TTM)
Gross Margin QoQ = -102.5% (prev -137.9%)
Tobins Q-Ratio = 0.34 (Enterprise Value 18.4m / Total Assets 54.1m)
Interest Expense / Debt = 4.54% (Interest Expense 553.1k / Debt 12.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -10.8m (EBIT -13.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.18 (Total Current Assets 4.40m / Total Current Liabilities 24.0m)
Debt / Equity = 0.49 (Debt 12.2m / totalStockholderEquity, last quarter 24.9m)
Debt / EBITDA = -0.92 (negative EBITDA) (Net Debt 9.17m / EBITDA -9.96m)
Debt / FCF = -1.80 (negative FCF - burning cash) (Net Debt 9.17m / FCF TTM -5.09m)
Total Stockholder Equity = 14.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.25% (Net Income -19.3m / Total Assets 54.1m)
RoE = -134.4% (Net Income TTM -19.3m / Total Stockholder Equity 14.3m)
RoCE = -70.23% (EBIT -13.7m / Capital Employed (Equity 14.3m + L.T.Debt 5.13m))
RoIC = -48.51% (negative operating profit) (NOPAT -10.8m / Invested Capital 22.2m)
WACC = 5.39% (E(9.27m)/V(21.5m) * Re(7.77%) + D(12.2m)/V(21.5m) * Rd(4.54%) * (1-Tc(0.21)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -28.28%
Fair Price DCF = unknown (Cash Flow -5.09m)
EPS Correlation: -76.46 | EPS CAGR: -13.54% | SUE: -2.23 | # QB: 0
Revenue Correlation: -93.14 | Revenue CAGR: -42.64% | SUE: -3.99 | # QB: 0